Monday, February 6, 2023
Google search engine
HomeMarketResultsHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2023 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2023 Earnings Guidance


Halozyme Therapeutics (NASDAQ:HALOGet Rating) issued an replace on its FY 2023 earnings steering on Tuesday morning. The corporate supplied earnings per share (EPS) steering of $2.50-$2.65 for the interval, in comparison with the consensus estimate of $2.90. The corporate issued income steering of $815.00 million-$845.00 million, in comparison with the consensus income estimate of $892.47 million.

Halozyme Therapeutics Inventory Efficiency

Halozyme Therapeutics stock traded up $0.66 throughout noon buying and selling on Tuesday, hitting $55.70. The corporate’s inventory had a buying and selling quantity of 504,898 shares, in comparison with its common quantity of 957,649. Halozyme Therapeutics has a 1-year low of $31.36 and a 1-year excessive of $59.46. The corporate has a debt-to-equity ratio of 15.37, a present ratio of 5.97 and a fast ratio of 5.03. The corporate has a 50-day shifting common value of $54.80 and a two-hundred day shifting common value of $47.95. The corporate has a market cap of $7.53 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 0.63 and a beta of 1.23.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) final issued its quarterly earnings information on Tuesday, November eighth. The biopharmaceutical firm reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.21. Halozyme Therapeutics had a web margin of 36.37% and a return on fairness of 134.71%. The enterprise had income of $208.98 million throughout the quarter, in comparison with analysts’ expectations of $187.87 million. As a gaggle, sell-side analysts predict that Halozyme Therapeutics will publish 2.07 earnings per share for the present yr.

Wall Road Analyst Weigh In

HALO has been the subject of a number of current analyst stories. Wells Fargo & Firm initiated protection on shares of Halozyme Therapeutics in a report on Monday, November twenty eighth. They issued an obese ranking and a $65.00 goal value on the inventory. Morgan Stanley raised their goal value on shares of Halozyme Therapeutics from $53.00 to $65.00 and gave the corporate an obese ranking in a report on Wednesday, December twenty first. StockNews.com initiated protection on shares of Halozyme Therapeutics in a report on Wednesday, October twelfth. They issued a maintain ranking on the inventory. JMP Securities raised their goal value on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the corporate a market outperform ranking in a report on Wednesday, November ninth. Lastly, Benchmark raised their goal value on shares of Halozyme Therapeutics from $55.00 to $68.00 and gave the corporate a purchase ranking in a report on Thursday, December eighth. One analyst has rated the inventory with a maintain ranking and 7 have issued a purchase ranking to the corporate’s inventory. Based mostly on information from MarketBeat.com, the corporate has a median ranking of Reasonable Purchase and a median value goal of $59.75.

Insider Exercise at Halozyme Therapeutics

In associated information, CEO Helen Torley bought 10,000 shares of Halozyme Therapeutics inventory in a transaction that occurred on Thursday, November seventeenth. The shares had been bought at a median value of $52.15, for a complete transaction of $521,500.00. Following the sale, the chief govt officer now immediately owns 587,177 shares of the corporate’s inventory, valued at roughly $30,621,280.55. The sale was disclosed in a authorized submitting with the Securities & Alternate Fee, which is on the market at the SEC website. In different Halozyme Therapeutics information, CFO Nicole Labrosse bought 5,000 shares of the enterprise’s inventory in a transaction that occurred on Tuesday, November fifteenth. The shares had been bought at a median value of $53.81, for a complete transaction of $269,050.00. Following the sale, the chief monetary officer now immediately owns 4,045 shares of the corporate’s inventory, valued at roughly $217,661.45. The transaction was disclosed in a authorized submitting with the Securities & Alternate Fee, which is on the market at this hyperlink. Additionally, CEO Helen Torley bought 10,000 shares of the enterprise’s inventory in a transaction that occurred on Thursday, November seventeenth. The inventory was bought at a median value of $52.15, for a complete transaction of $521,500.00. Following the sale, the chief govt officer now immediately owns 587,177 shares within the firm, valued at $30,621,280.55. The disclosure for this sale will be discovered here. Within the final three months, insiders have bought 65,000 shares of firm inventory valued at $3,637,650. 2.30% of the inventory is owned by insiders.

Institutional Buyers Weigh In On Halozyme Therapeutics

Institutional buyers have just lately added to or lowered their stakes within the enterprise. Point72 Hong Kong Ltd acquired a brand new place in shares of Halozyme Therapeutics within the 2nd quarter price roughly $156,000. Captrust Monetary Advisors lifted its place in shares of Halozyme Therapeutics by 15.6% within the 2nd quarter. Captrust Monetary Advisors now owns 3,902 shares of the biopharmaceutical firm’s inventory price $172,000 after buying an extra 528 shares throughout the interval. Brinker Capital Investments LLC acquired a brand new place in shares of Halozyme Therapeutics within the 1st quarter price roughly $208,000. Vanguard Customized Indexing Administration LLC acquired a brand new place in shares of Halozyme Therapeutics within the 2nd quarter price roughly $246,000. Lastly, Walleye Capital LLC acquired a brand new place in shares of Halozyme Therapeutics within the 2nd quarter price roughly $500,000. 96.32% of the inventory is owned by institutional buyers.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma know-how platform firm in america, Switzerland, Eire, Belgium, Japan, and internationally. The corporate’s merchandise are based mostly on the ENHANZE drug supply know-how, a patented recombinant human hyaluronidase enzyme (rHuPH20) that allows the subcutaneous supply of injectable biologics, equivalent to monoclonal antibodies and different therapeutic molecules, in addition to small molecules and fluids.

Featured Articles

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

This immediate information alert was generated by narrative science know-how and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Halozyme Therapeutics, you may need to hear this.

MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Halozyme Therapeutics wasn’t on the record.

Whereas Halozyme Therapeutics presently has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here

(Almost) Everything You Need To Know About The EV Market Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments